Arena Pharmaceuticals Inc

Arena Pharmaceuticals — Investor Presentation (October 2020)

32 slides from Arena Pharmaceuticals's investor presentation, Oct 26, 2020

  1. Slide 1: Atopic Dermatitis Overview

    Nasdaq: ARNA • October 2020 Atopic Dermatitis Overview Exhibit 99.1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes forward-looking statements that involve a number of risks and uncertainties, including statements about our investigative-stage drug candidate etrasimod, including with respect to its potential (including to become first- or best-in-class), safet

  3. Slide 3: Atopic Dermatitis (AD) Disease State and Pathophysiology

    Atopic Dermatitis (AD) October 2020 • Disease State and Pathophysiology

  4. Slide 4: Etrasimod Aims to Address Unmet Need in Atopic Dermatitis

    Etrasimod Aims to Address Unmet Need in Atopic Dermatitis October 2020 • 1. Bieber T. NEJM 2008, 358;14: 1483-1494; 2: Guttman-Yassky et al. JACI 2011; 127(6):1420-1431; 3. Renert-Yuval Y and Guttman-Yassky E. AAAI 2020, 124:28-35 1. 4. Silverberg, JI. Dermatol Clin. 2017 Jul;35(3):283-289.; 5. Barb

  5. Slide 5: AD Associated with High Prevalence in Developed Countries and Significantly Impacts Quality of Life

    AD Associated with High Prevalence in Developed Countries and Significantly Impacts Quality of Life (QOL) October 2020 • Children Adults ~16.5 million US adults have a diagnosis of AD (~7.3% of the population). Of those Adults with AD, 40% (6.6 million) reporting moderate-to-severe symptoms1,5 AD is

  6. Slide 6: Mounting Evidence Points to AD as a Systemic Disorder

    Mounting Evidence Points to AD as a Systemic Disorder October 2020 • Higher immune activation recently reported in peripheral blood from AD vs. psoriasis patients: Increased activated T cells1,2 Increase in cytokine-producing T cells1,2 Associated with increased risk for systemic comorbidities: ...b

  7. Slide 7: Overlapping Disease Biology In UC, Psoriasis and AD

    Overlapping Disease Biology In UC, Psoriasis and AD Compelling Clinical Data Generated in UC and PsO With S1P1 Modulators October 2020 • 1. Sandborn WJ, et al. Gastroenterology. 2020;158(3):550-561. ; 2. Ungaro R, et al. Lancet. 2017;389(10080):1756-1770. ; 3. Lowes MA, et al. Annu Rev Immunol. 2014

  8. Slide 8: Systematic Review Reveals Bidirectional Association Between AD and IBD

    Recently Published Systematic Review and Meta-Analysis Reveals Bidirectional Association Between AD and IBD October 2020 • Lee H, et al. J Am Acad Dermatol. 2020;S0190-9622(20)31006-9. Subgroup meta-analyses of Ulcerative Colitis (UC) and Crohn’s Disease (CD) showed that UC has a bidirectional assoc

  9. Slide 9: AD is a Heterogenous Biphasic Disease Mediated by Broad Range of Cytokines

    AD is a Heterogenous Biphasic Disease Mediated by Broad Range of Cytokines Acute FlareChronic State October 2020 • Cytokine milieu in AD thought to be influenced by multiple factors1: Stage of disease Ethnicity Age Klonowska J, et al. Int J Mol Sci. 2018;19(10):3086. Image Source: Leung DY, Guttman-

  10. Slide 10: During an Acute Flare, Staphylococcus aureus Exploits Epidermal Barrier Defects in AD

    During an Acute Flare, Staphylococcus aureus Exploits Epidermal Barrier Defects in AD to Trigger Cytokine Expression1,2,3 1. Nakatsuji T, et al. J Invest Dermatol. 2016;136(11):2192-2200. ; 2. Leung DY, Guttman-Yassky E. J Allergy Clin Immunol. 2014;134(4):769-779.; 3. Kim J, Kim BE, Leung DYM. Alle

  11. Slide 11: Etrasimod Reduced Trafficking of Dendritic Cells and T Cell Activation in Pre-Clinical AD Model

    Etrasimod Reduced Trafficking of Dendritic Cells From Skin to Lymph Node and Reduced T Cell Activation in Lymph Nodes in Pre-Clinical AD Model 1. Crosby C, et al. Poster Presented at Revolutionizing Atopic Dermatitis virtual Symposium; April 2020. Poster #159. October 2020 • Data in Mice Lymph Nodes

  12. Slide 12: Etrasimod Led to Fewer T Cells, B Cells, and Eosinophils

    Etrasimod Led to Fewer T Cells, B Cells, and Eosinophils Which are Thought to be Mediators of Inflammation in Atopic Dermatitis October 2020 • 1. Crosby C, et al. Poster Presented at Revolutionizing Atopic Dermatitis virtual Symposium; April 2020. Poster #159 3 Acute Flare: Th2 Inflammation Chronic

  13. Slide 13: Reduced Trafficking of T Cells Correlated with Decreased Tissue Cytokines

    3 Acute Flare: Th2 Inflammation Chronic Disease State: Heterogeneous Th1/Th2/Th17 Inflammation Reduced Trafficking of T Cells Correlated with Decreased Tissue Th2, Th1 and Th17 Cytokines Relevant to Acute Flare and Chronic Disease State 1. Crosby C, et al. Poster Presented at Revolutionizing Atopic

  14. Slide 14: Th1, Th22 and Th17 are Significant Mediators of Disease in the Chronic Phase

    In Addition to Th2 T cells, Th1, Th22 and Th17 are Significant Mediators of Disease in the Chronic Phase October 2020 • 1. Zhou L, et al. J Allergy Clin Immunol. 2019;144(1):144-156. ; 2. Renert-Yuval Y, Guttman-Yassky E. Ann Allergy Asthma Immunol. 2020;124(1):28-35. AD is characterized by activati

  15. Slide 15: Upstream Mechanism of Etrasimod May Interrupt Multiple Pathways in Acute Flare and Chronic AD

    Based on Pre-Clinical Data, Upstream Mechanism of Etrasimod May Interrupt Multiple Pathways that Mediate Acute Flare and Chronic AD October 2020 • 1. Crosby C, et al. Poster Presented at Revolutionizing Atopic Dermatitis virtual Symposium; April 2020. Poster #159 3 Acute Flare: Th2 Inflammation Chro

  16. Slide 16: Etrasimod MOA May Address Mediators of Acute Flare and Chronic Phases of AD

    October 2020 • Definitions: DC, dendritic cell; IL, interleukin; MOA, mechanism of action; Th, T helper cell; S1P, sphingosine-1-phosphate *Statements are aspirational in nature and not intended to be based on direct evidence at this stage in the program Etrasimod MOA May Address Mediators of Acute

  17. Slide 17: Market Opportunity

    Market Opportunity October 2020 •

  18. Slide 18: Multiple New Product Entrants Projected to Grow AD Market to $24B by 2028

    October 2020 • Abbreviations: CAGR, compound annual growth rate; DRG, Dieringer Research Group (marketing research group); IL, interleukin; JAK, janus kinase; PDE4, phosphodiesterase 4 1. Source: DRG AD Disease Landscape & Forecast 2019’ *Note: based on SCORAD (children aged 0-14), PO-SCORAD (patien

  19. Slide 19: Safety and Simplicity Heavily Influence Dermatologists' Treatment Decisions

    0%50%100% Safety and Simplicity Heavily Influence Dermatologists’ Treatment Decisions October 2020 • http://www.pmlive.com/pharma_news/amgen_raises_forecasts_after_closing_$13.4bn_otezla_deal_1317936#:~:text=Otezla%20is%20the%20leader%20in,as%20AbbVie's%20Humira%20(adalimumab). Otezla. Package inser

  20. Slide 20: Dermatologists' JAK Safety Perceptions are Shaping Their View of the Class

    Dermatologists’ JAK Safety Perceptions are Shaping Their View of the Class and Future Intended Use October 2020 • Abbreviations: RA, rheumatoid arthritis; JAK, janus kinase Source: Spherix AD Q2 2020 Survey questions: Although these risk factors have not been witnessed in clinical trials for AD, in

  21. Slide 21: In 2017, Dupilumab was First Advanced Line Agent Approved for AD in ~15 years

    In 2017, Dupilumab was First Advanced Line Agent Approved for AD in ~15 years October 2020 • Adults 12-17Y 6-11Y <6Y Prevalence 8,200 2,500 2,500 2,400 Moderate-to-severe 2,600 800 700 700 Biologics eligible 1,700 400 90 75 74 8 Approved 2022e Share of Biologics eligible 4.4% 2.0% U.S. AD population

  22. Slide 22: High-Dose JAK Agents Have Encountered Regulatory Challenges

    In the US High-Dose JAK Agents Have Encountered Regulatory Challenges with Both Product Approvals and Product Labeling October 2020 • Sources: https://www.biopharmadive.com/news/fda-boxed-warning-for-abbvies-jak-inhibitor-clouds-gileads/561186/ (Aug 16, 2019 ;https://www.ema.europa.eu/en/news/ema-co

  23. Slide 23: Need to Target Immune Axes Beyond IL-4/IL-13

    October 2020 • 1. Renert-Yuval Y, Guttman-Yassky E. Ann Allergy Asthma Immunol. 2020;124(1):28-35. For new treatments to address the unique fingerprint of each AD subtype, targeting of other immune axes beyond IL-4/IL-13 is needed. It likely will be necessary to target a combination of cytokines to

  24. Slide 24: Competitive Landscape

    Competitive Landscape October 2020 •

  25. Slide 25: ADVISE Ph 2b Trial Design

    ADVISE Ph 2b Trial – 12 Week Efficacy Period Followed by 52 Week Open-Label Extension Open-label (52 weeks) Overall trial duration of 76 weeks Day 1 Week 16 Screening Period 12-Week Treatment Period Follow-up Period Week 12 4-Week Wash out < 4 Weeks Baseline EASI Week 68 Week 72 4-Week Follow-up Oct

  26. Slide 26: Cross-Trial Comparison of Phase 2 Trials

    Cross-Trial Comparison Suggest Disease Duration and Baseline Severity May Influence Treatment Effect (Ph 2 Trials) October 2020 • Abbreviations: AD, atopic dermatitis; AE, adverse event; BSA, body surface area; EASI, Eczema and Severity Index; IGA, Investigator Global Assessment Scale for AD; NRS, n

  27. Slide 27: EASI-75 Peak Response: Dupilumab and Upadacitinib Patients Stop Improving Between Weeks 8-12

    EASI-75 Peak Response: Dupilumab and Upadacitinib Patients Stop Improving Between Weeks 8-12 October 2020 • 1. Thaçi D, et al. J Dermatol Sci. 2019;94(2):266-275. ; 2. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2020;145(3):877–884. Mean (± SE) EASI over time1 Mean (± SE) % Improvement From Bas

  28. Slide 28: Atopic Dermatitis Ph 2b Trials Percent Change EASI at Week 12

    Atopic Dermatitis Ph 2b Trials Percent Change EASI from Baseline at Week 12 October 2020 • 1. Wollenberg A, et al. J Allergy Clin Immunol. 2019;143(1):135-141. ; 2. Guttman-Yassky E, et al. JAMA Dermatol. 2020;156(4):411‐420. ; 3. Thaçi D, et al. Lancet. 2016;387(10013):40‐52. ; 4. Gooderham MJ, et

  29. Slide 29: Placebo Adjusted EASI Improvement Competitive Landscape at Week 12

    Placebo Adjusted EASI 75 Improvement from Baseline Atopic Dermatitis Ph 2b Competitive Landscape at Week 12 October 2020 • Note: No direct head-to-head data available; Caution advised when comparing data across clinical trials tralokinumab1 Lebrikizumab2 dupilumab3 abrocitinib4 baricitinib5 upadacit

  30. Slide 30: Placebo Adjusted IGA 0/1 Improvement Competitive Landscape at Week 12

    Placebo Adjusted IGA 0/1 Improvement from Baseline Across Atopic Dermatitis Ph 2b Competitive Landscape at Week 12* October 2020 • *dupilumab values reflect Week 16 results, as Week 12 results are not available in the public domain Note: No direct head-to-head data available; Caution advised when co

  31. Slide 31: Etrasimod Potential Best-in-Class S1P Receptor Modulator

    Etrasimod Potential Best-in-Class S1P Receptor Modulator with Opportunity for Broad Applicability 1. Sandborn WJ, et al. Gastroenterology. 2020;158(3):550-561. ; 2. Vermeire S, et al. Poster Presented at United European Gastroenterology Week (UEGW); October 2019. Poster #P0403 October 2020 • Recepto

  32. Slide 32: Arena Pharmaceuticals

    /AARI-NA PHARMACEUTICALS Nasdaq: ARNA

Arena Pharmaceuticals — Investor Presentation (October 2020) on 6ix